Key result
Olaratumab plus doxorubicin improves overall survival versus doxorubicin alone in unresectable soft tissue sarcoma.
Why the study?
The outcome for patients with unresectable/metastatic soft tissue sarcoma remains poor with few treatment options and no overall survival difference between combination anthracycline schedules and single agent doxorubicin.
Does olaratumab combined with doxorubicin improve overall survival in adult patients with anthracycline-naive unresectable soft tissue sarcoma?
Does olaratumab combined with doxorubicin improve overall survival in adult patients with anthracycline-naive unresectable soft tissue sarcoma?
Olaratumab combined with doxorubicin improves overall survival in adult patients with anthracycline-naive unresectable soft tissue sarcoma, leading to its approval.
Answers are grounded in this paper and cite their sources.
Supports first-line olaratumab plus doxorubicin in unresectable soft tissue sarcoma; extends targeted therapy beyond failed chemotherapy combinations.
The outcome for patients with unresectable/metastatic soft tissue sarcoma remains poor with few treatment options. In the first line setting, a number of randomized trials have shown no difference in overall survival between combination anthracycline schedules and single agent doxorubicin. A Phase Ib/randomized Phase II trial of doxorubicin with or without the monoclonal antibody to PDGFR-α, olaratumab, demonstrated a significant difference in median overall survival in favor of the olaratumab arm. The results of this trial led to approval of olaratumab in combination with doxorubicin in adult anthracycline-naive unresectable soft tissue sarcoma. In this review, we describe some of the preclinical and early clinical data of olaratumab in sarcomas, the Phase Ib/II trial and ongoing trials with olaratumab in sarcomas.
No takes yet. Share an insight, caveat, or question.
Pender et al. (2017) conducted a review in unresectable/metastatic soft tissue sarcoma. Olaratumab vs. Doxorubicin alone was evaluated. Olaratumab combined with doxorubicin demonstrated a significant improvement in median overall survival compared to doxorubicin alone in patients with unresectable soft tissue sarcoma.
Synapse has enriched 10 related papers. Consider them for comparative context: